Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria~  1. Postmenopausal women (one year after menses stop)~ 2. Confirmed diagnosis of breast cancer~ 3. Tumors with higher expression PR \> 50 % measured by IHC and PRA/RPB ratio equal or higher than 1.5 measured by WB~ 4. All clinical stages with tumor size greater than 1.5 cm to allow obtaining material from biopsy cores~ 5. OMS condition: 1 Adequate function of organs and systems~Hematopoietic parameters:~* Hemoglobin: 10 gr/mL~* Neutrophil counting: 1.500/mm3~* CD4 counting: 400/mm3~* Platelets counting: 100.000/mm3 Liver parameters~* Total albumin: 1.5 fold normal limit~* AST/ALT: 1.5 fold normal limit Renal~* Creatinine: 1.5 fold normal limit 6. Absence of other controlled disease 7. Patients willing to sign consent~Exclusion Criteria:~* Exclusion criteria~  1. Patients with no recommended surgery~ 2. Patients which have received any other treatment for this cancer~ 3. Patients expressing ER but expressing PRA/PRB levels lower than 1.5~ 4. Hepatitis infection (HBV o HCV)~ 5. HIV infection.~ 6. Cognitive alterations which limit the understanding of the protocol or compliance to the protocol~ 7. Prolonged QT/QTc basal interval

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).